Company: DRTSW
Filing Date: 2025-06-23
Form Type: F-3
Source: 0001213900-25-056744
Chunk: 16

Company: Alpha Tau Medical Ltd.
Filing Date: 2025-06-23
Form: F-3
Chunk 16
---
” on page 6 for a discussion of certain factors that should                                                                                                                                                                                                                                                                                                                                       
 be considered before buying the securities offered hereby.                                                                                                                                                                                                                                                                                                                                                                                             |

<div align='center'>5

RISK FACTORS</div>

You should carefully consider the risks described below and the risks described in the documents incorporated by reference herein, including our Annual Report, as well as the other information included in this prospectus or incorporated by reference in this prospectus before you decide to buy our securities. The risks and uncertainties described below are not the only risks facing us. We may face additional risks and uncertainties not currently known to us or that we currently deem to be immaterial. Any of the risks described below, and any such additional risks, could materially adversely affect our business, financial condition or results of operations. In such case, you may lose all or part of your original investment.

Risks Related to this Offering

Sales of a substantial number of our securities in the public market by the Selling Shareholders and/or by our existing securityholders could cause the price of our ordinary shares to fall.

The Selling Shareholders
can sell, under this prospectus, up to 3,463,202 ordinary shares constituting approximately 3.9% of our issued and outstanding ordinary
shares as of June 20, 2025 after giving effect to the exercise in full of the IR/PR Warrants. Sales of a substantial number of ordinary
shares in the public market by the Selling Shareholders and/or by our other existing securityholders, or the perception that those sales
might occur, could depress the market price of our ordinary shares and could impair our ability to raise capital through the sale of additional
equity securities. We are unable to predict the effect that such sales may have on the prevailing market price of our ordinary shares.

Our ordinary share price is and may continue to be volatile and you may not be able to resell our securities at or above the price you paid.

The market price for our
ordinary shares is volatile and may fluctuate significantly in response to a number of factors, most of which we cannot control, such
as fluctuations in financial results, our ability to advance the development of our product candidates or changes in securities analysts’
recommendations. In addition, our ordinary shares have been and may continue to be affected by limited trading volume. Each of these factors,
among others, could harm your investment in our ordinary shares and could result in you being unable to resell the ordinary shares that
you purchased at a price equal to